Lyra Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Point72 Asset Management, L.P.(0%),Point72 Capital Advisors, Inc.(0%)等
Lyra Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Samsara BioCapital, L.P.(4.98%),Samsara BioCapital GP, LLC(4.98%)等
Lyra Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Venrock Healthcare Capital Partners II, L.P.(1.8%),VHCP Co-Investment Holdings II, LLC(1.8%)等
Lyra Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Vestal Point Capital, LP(0%),Ryan Wilder(0%)
Lyra Therapeutics | 4:持股变动声明-高管 Palasis Maria
Lyra Therapeutics | 4:持股变动声明-高管 Cavalier Jason
Lyra Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-Perceptive Advisors LLC(19.5%),Joseph Edelman(19.5%)等
Lyra Therapeutics | 4:持股变动声明-董事 ALTMAN MICHAEL SETH
Lyra Therapeutics | 4:持股变动声明-董事 Poukalov Konstantin
Lyra Therapeutics | 4:持股变动声明-董事 TOBIN JAMES R
Lyra Therapeutics | 4:持股变动声明-董事 snyderman nancy lynn MD
Lyra Therapeutics | 4:持股变动声明-董事 Smith W Bradford
Lyra Therapeutics | 4:持股变动声明-董事 MERRIFIELD C ANN
Lyra Therapeutics | 4:持股变动声明-高管 Waksal Harlan
Lyra Therapeutics | 4:持股变动声明-高管 Palasis Maria
Lyra Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Venrock Healthcare Capital Partners II, L.P.(9.999%),VHCP Co-Investment Holdings II, LLC(9.999%)等
Lyra Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Citadel Advisors LLC(7.9%),Citadel Advisors Holdings LP(7.9%)等
Lyra Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Steven A. Cohen(5.8%),Point72 Asset Management, L.P.(5.7%)等
Lyra Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Nantahala Capital Management, LLC(8.9%),Wilmot B. Harkey(8.9%)等
Lyra Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-Perceptive Advisors LLC(24.3%),Joseph Edelman(24.3%)等